Related Experiment Video
Updated: Mar 23, 2026
08:14
Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research
Published on: March 22, 2024
2.1K
RECOMBINANT BCL-XL ATTENUATES VASCULAR HYPERPERMEABILITY IN A RAT MODEL OF HEMORRHAGIC SHOCK
Binu Tharakan1, Sam I McNeal2, Felicia A Hunter2
1Department of Surgery, Texas A&M University Health Science Center College of Medicine and Baylor Scott & White Healthcare, Temple, TX. USA.
Cell Death Discovery
|April 5, 2016
Summary
Recombinant Bcl-xL protein effectively reduces vascular hyperpermeability following hemorrhagic shock (HS) by preserving mitochondrial function and inhibiting apoptosis. This novel treatment also decreases fluid resuscitation needs and protects against cellular damage.
Area of Science:
- Cardiovascular Research
- Cellular Biology
- Trauma Medicine
Background:
- Hemorrhagic shock (HS) causes vascular hyperpermeability due to disrupted endothelial cell junctions.
- Mitochondrial-mediated apoptosis signaling plays a key role in HS-induced vascular leakage.
- Endothelial cell-cell adherens junctional complex disruption leads to fluid and protein extravasation.
Purpose of the Study:
- To investigate the novel use of recombinant Bcl-xL, an anti-apoptotic protein, in controlling HS-induced vascular hyperpermeability.
- To elucidate the role of apoptotic signaling pathways in HS-induced vascular dysfunction.
- To assess the therapeutic potential of Bcl-xL in mitigating the effects of hemorrhagic shock.
Main Methods:
- Hemorrhagic shock was induced in rats by reducing mean arterial pressure (MAP) to 40 mmHg for 60 minutes, followed by resuscitation.
- Intra-vital microscopy was used to assess vascular hyperpermeability.
- Recombinant Bcl-xL or Bcl-xL inhibitors (2-methoxy antimycin, ABT 737) were administered intravenously. Mitochondrial function markers (ROS, ΔΨm, cytochrome c release) and caspase-3 activation were measured.
Main Results:
- Bcl-xL treatment significantly attenuated or reversed HS-induced vascular hyperpermeability (p<0.05).
- Bcl-xL inhibitors exacerbated vascular hyperpermeability compared to sham controls (p<0.05).
- Bcl-xL treatment reduced fluid volume requirements during resuscitation and inhibited HS-induced mitochondrial dysfunction and caspase-3 activation (p<0.05).
Conclusions:
- Recombinant Bcl-xL is effective in combating HS-induced vascular hyperpermeability.
- The protective effects of Bcl-xL involve preserving mitochondrial membrane potential (ΔΨm) and preventing caspase-3 activation.
- Bcl-xL represents a promising therapeutic agent for managing vascular complications associated with hemorrhagic shock.
